melanotan.2 Melanotan II 10mg Research Peptide (MT2) Melanotan II (MT-II) Peptide Therapy

Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, Biaggioni I, Ertl A, Black B, Robertson D

Accessed April 1, 2018

Outcome and follow up Anthropometric and clinical parameters, biochemical data and bone age were regularly assessed during the follow-up

(30 ml)

Am J Hum Genet 42:422434 Pomerantz DJ, Ferdinandusse S, Cogan J, Cooper DN, Reimschisel T, Robertson A, Bican A, McGregor T, Gauthier J, Millington DS, Andrae JLW, Tschannen MR, Helbling DC, Demos WM, Denis S, Wanders RJA, Newman JN, Hamid R, Phillips JA III, UDN Co (2018) Clinical heterogeneity of mitochondrial NAD kinase deficiency caused by a NADK2 start loss variant